2023
Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial
Kann B, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly H, Juliano A, Payabvash S, Guenette J, Uppaluri R, Margalit D, Schoenfeld J, Tishler R, Haddad R, Aerts H, Garcia J, Flamand Y, Subramaniam R, Burtness B, Ferris R. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. The Lancet Digital Health 2023, 5: e360-e369. PMID: 37087370, PMCID: PMC10245380, DOI: 10.1016/s2589-7500(23)00046-8.Peer-Reviewed Original ResearchConceptsExtranodal extensionOropharyngeal carcinomaShort-axis diameterChallenging cohortPathology reportsECOG-ACRIN Cancer Research GroupDe-escalation trialsCancer Research GroupDe-escalation strategiesSurgical pathology reportsNational Cancer InstituteInter-reader agreementLargest short-axis diameterPostoperative chemoradiationProtocol exclusionsConcurrent chemoradiationPrimary endpointMulticentre trialPretreatment CTAdjuvant strategiesHuman papillomavirusTreatment selection toolUS National InstitutesPretreatment identificationStudy protocol
2019
Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.Peer-Reviewed Original ResearchConceptsDe-escalate treatmentOropharyngeal carcinomaHPV-positive oropharyngeal carcinomaNeck cancer clinical researchNew systemic agentsPhase II trialPhase III trialsTreatment-related morbidityHigh cure ratesCancer clinical researchConcurrent cisplatinII trialOropharynx cancerPrimary surgeryDose intensityIII trialsInstitutional seriesInvasive resectionMultimodality treatmentSystemic agentsSystemic therapyPrimary diseaseCure rateToxic therapiesMultimodality strategy
2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet 2018, 393: 40-50. PMID: 30449625, PMCID: PMC6541928, DOI: 10.1016/s0140-6736(18)32779-x.Peer-Reviewed Original ResearchConceptsHPV-positive oropharyngeal carcinomaProgression-free survivalOverall survivalNon-inferiority trialCisplatin groupCetuximab groupOropharyngeal carcinomaSevere toxicityEligibility criteriaPositive oropharyngeal squamous cell carcinomaHuman papillomavirus-positive oropharyngeal cancerNational Cancer Institute-USAZubrod performance status 0Oropharyngeal squamous cell carcinomaAdequate bone marrowPerformance status 0Replacement of cisplatinZubrod performance statusInferior overall survivalTobacco smoking historyAmerican Joint CommitteeNon-inferiority criteriaSquamous cell carcinomaStandard of careNon-inferiority marginPatterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma
Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeck DissectionNeoplasm MetastasisNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPapillomavirus InfectionsProgression-Free SurvivalProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyConceptsProgression-free survivalInvolved lymph nodesDistant metastasisPatterns of failureLocoregional recurrenceLymph nodesHuman papillomavirus-positive oropharyngeal carcinomaMultivariate analysisEdition American Joint CommitteeRate of DMWorse progression-free survivalHigh DM rateDedicated clinical trialsAmerican Joint CommitteeCancer (AJCC) staging systemProportional hazards regressionExternal beam radiationOropharynx cancerFree survivalNeck dissectionOropharyngeal carcinomaOverall survivalDisease recurrenceIntraoperative brachytherapyOPC patients
2010
SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia
Turaka A, Weinberg B, Li T, Nicos N, Burtness B, Lango M, Ridge J, Feigenberg S. SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia. Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468568.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyParotid gland volumeRT dosesPercent weight lossWeight lossGland volumeMedian percent weight lossUse of IMRTPG volumesFox Chase Cancer CenterGrade 3 xerostomiaAddition of chemotherapyLocoregional control rateOverall survival rateSquamous cell cancerWeeks of treatmentPatterns of failureCurative intentMedian followToxicity scoringDefinitive RTMedian doseNeck dissectionOropharyngeal carcinomaMedian age